This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Rohto Pharmaceutical Co., Ltd.. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2023
Title: Mihoko Yoshino: Innovator in Mesenchymal Stem Cell Research
Introduction
Mihoko Yoshino is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of mesenchymal stem cell research, focusing on innovative methods for preparing and utilizing these cells in therapeutic applications. With a total of 2 patents, her work is paving the way for advancements in medical treatments.
Latest Patents
Yoshino's latest patents include groundbreaking inventions related to ROR1-positive mesenchymal stem cells. These patents encompass a method for preparing ROR1-positive mesenchymal stem cells, a pharmaceutical composition containing these cells, and a method for preventing or treating diseases using them. The objective of her inventions is to provide novel mesenchymal stem cells that demonstrate superior therapeutic effects against various diseases. The ROR1-positive mesenchymal stem cells are characterized by their positivity for specific cell surface markers, including CD29, CD73, CD90, CD105, and CD166, and are derived from umbilical cord or adipose tissue.
Career Highlights
Mihoko Yoshino is currently associated with Rohto Pharmaceutical Co., Ltd., where she continues her research and development efforts. Her work is instrumental in advancing the understanding and application of mesenchymal stem cells in the medical field.
Collaborations
Yoshino collaborates with notable colleagues, including Hiroyuki Nishida and Masayo Yumoto, who contribute to her research endeavors. Their combined expertise enhances the potential impact of their work in the field of regenerative medicine.
Conclusion
Mihoko Yoshino's innovative research in mesenchymal stem cells represents a significant advancement in therapeutic applications. Her contributions are expected to lead to improved treatment options for various diseases, showcasing the importance of her work in the medical community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile